# NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers

> **NCT02721056** · PHASE1,PHASE2 · TERMINATED · sponsor: **Nanobiotix** · enrollment: 23 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **RADIATION:** NBTXR3, IL or IA injection + SBRT

## Key facts

- **NCT ID:** NCT02721056
- **Lead sponsor:** Nanobiotix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01-28
- **Primary completion:** 2020-05-06
- **Final completion:** 2020-05-06
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** The RP2D for intratumoral injection was determined. With the changing practice of medicine for HCC, it was decided to design an independent Phase II clinical study.
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02721056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02721056, "NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02721056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*